The use of maggot therapy (MT) is proving effective in the treatment of complicated diabetic foot ulcers (DFUs). Most of the previous studies have focused on the comparison of MT and routine treatment approaches for the management of DFUs. The aim of this study was to add MT to routine treatment line of DFUs as a new approach. In this study, the principal expectation from MT method was to prepare wound bed for continuation of the treatment with other measures. This study was designed as a before-after observational study. Twenty-five out of the initial 47 volunteers who presented with DFUs to our wound clinic were included in our study. In the present study, a total of 27 DFU cases were managed with maggot therapy using the Karaj Strain of Lucilia sericata (L. sericata). MT was added to routine treatments as a complementary therapy. Surface areas of the necrotic tissues and granulation tissues over time were calculated. Satisfaction of patients and physicians was evaluated with a questionnaire. There was a significant reduction in the surface area of necrotic tissues and increase in the surface area of granulation tissues (p < 0.0001) as early as four days after the initiation of maggot therapy. After adjusting for confounding variables, statistical analysis confirmed a significant reduction in the size of necrotic tissues and increase in granulation tissues formation (p < 0.001). About 96.3% of the physicians and patients involved in our study were satisfied with the results of the treatment. The time for significant reduction of the size of necrotic tissues was less than in similar studies. This study confirmed that effective, faster and satisfactory results can be achieved when MT is added to routine treatments as a complementary therapy for healing DFUs. This approach can be introduced as a new treatment modality for healing DFUs with high rate success.
References
1.
Spessotto CV, Cavalli H, Eboni ACB, Machado RB, Mousquer AM, Palazzo LB, et al. Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis. Arquivos de Neuro-Psiquiatria. 2016;74(8):617–20.
2.
Spilsbury K, Cullum N, Dumville J, O’Meara S, Petherick E, Thompson C. Exploring patient perceptions of larval therapy as a potential treatment for venous leg ulceration. Health Expectations. 2008;11(2):148–59.
3.
Petherick E, O’Meara S, Spilsbury K, Iglesias C, Nelson E, Torgerson D. Patient acceptability of larval therapy for leg ulcer treatment: a randomised survey to inform the sample size calculation of a randomised trial. BMC Medical Research Methodology. 2006;6(1).
4.
Sherman RA. Maggot Therapy Takes Us Back to the Future of Wound Care: New and Improved Maggot Therapy for the 21st Century. Journal of Diabetes Science and Technology. 2009;3(2):336–44.
5.
Cavuşoglu T, Apan T, Eker E, Vargel I, Saray A. Massive oculofacial myiasis infestation with Lucilia sericata. Journal of the American Academy of Dermatology. 2009;61(1):169–70.
6.
Yasin M, Moghhtader Mojhdehi A, Haghighi M, Akbarzadeh K. Ophthalmomyiasis and Basal Cell Carcinoma: a Case Report. Archives of Clinical Infectious Diseases. 8(3).
7.
Alizadeh M, Mowlavi G, Kargar F. A Review of Myiasis in Iran and a New Nosocomial Case from Tehran, Iran. J Arthropod-borne Dis. 2014;8(2).
8.
Wang S, Wang J, Lv D, Diao Y, Zhang Z. Clinical research on the bio‐debridement effect of maggot therapy for treatment of chronically infected lesions. Orthopaedic Surgery. 2010;2(3):201–6.
9.
Sherman RA. Maggot Therapy for Treating Diabetic Foot Ulcers Unresponsive to Conventional Therapy. Diabetes Care. 2003;26(2):446–51.
10.
Prete PE. Growth effects of Phaenicia sericata larval extracts on fibroblasts: Mechanism for wound healing by maggot therapy. Life Sciences. 1997;60(8):505–10.
11.
Gottrup F, Jørgensen B. Maggot debridement: an alternative method for debridement. Eplasty. 2011;11.
12.
Jain AKC. A new classification of diabetic foot complications: a simple and effective teaching tool. J Diab Foot Comp. 2012;4(1):1–5.
13.
Sen S, Fawson P, Cherrington G, Douglas K, Friedman N, Maljanian R, et al. Patient Satisfaction Measurement in the Disease Management Industry. Disease Management. 2005;8(5):288–300.
14.
Organization WH. Global report on diabetes: executive summary. 2017;
15.
Nishijima A, Gosho M, Yoshida R, Yanagibayashi S, Takikawa M, Nishijima J, et al. Effective wound bed preparation using maggot debridement therapy for patients with critical limb ischaemia. Journal of Wound Care. 2017;26(8):483–9.
16.
Falanga V. Wound Bed Preparation in Practice. EWMA Position Document. 2004;2–5.
17.
m. Bio-debridment of wounds. A thesis for PhD Degree. Baghyatallah university of medical scinces. 2006;
18.
Sherman RA, Hall MJR, Thomas S. Medicinal Maggots: An Ancient Remedy for Some Contemporary Afflictions. Annual Review of Entomology. 2000;45(1):55–81.
19.
SHERMAN RA, PECHTER EA. Maggot therapy: a review of the therapeutic applications of fly larvae in human medicine, especially for treating osteomyelitis. Medical and Veterinary Entomology. 1988;2(3):225–30.
20.
CHERNIN E. Surgical Maggots. Southern Medical Journal. 1986;79(9):1143–5.
21.
Parnés A, Lagan KM. Larval therapy in wound management: a review. International Journal of Clinical Practice. 61(3):488–93.
22.
Marineau ML, Herrington MT, Swenor KM, Eron LJ. Maggot debridement therapy in the treatment of complex diabetic wounds. Hawaii Med J. 2011;70(6):121–4.
23.
Zarchi K, Jemec GB. The efficacy of maggot debridement therapy – a review of comparative clinical trials. International Wound Journal. 2012;9(5):469–77.
24.
Sun X, Jiang K, Chen J, Wu L, Lu H, Wang A, et al. A systematic review of maggot debridement therapy for chronically infected wounds and ulcers. International Journal of Infectious Diseases. 2014;25:32–7.
25.
Moxey PW, Gogalniceanu P, Hinchliffe RJ, Loftus IM, Jones KJ, Thompson MM, et al. Lower extremity amputations - a review of global variability in incidence. Diabetic Medicine. 2011;28(10):1144–53.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
